By Lydia Charney
There are an estimated 20 million women infected with HIV, or human immunodeficiency virus, worldwide. This sexually transmitted disease can lead to acquired immunodeficiency syndrome, commonly known as AIDS.
HIV is the leading cause of death for African American women aged 25-34 years, according to the Center of Disease Control and Prevention.

African American women represent the largest demographic of HIV infected women.
”It is certainly true that HIV/AIDS is a disease that younger people are more likely to acquire than older people,” reported Dr. George Schmid, a medical officer with the World Health Organization, about the unexplored story of HIV and aging.

However, scientists have developed a topical preventive method for women, in hopes of reducing these startling statistics.
A microbicide gel has for the first time shown some promise to prevent HIV infection in women in a clinical trial involving more than 3,000 subjects in the U.S. and southern Africa, according to Global Coalition on Women and AIDS.

The high prevelance of AIDS in South Africa makes is a prime location for clinical microbicide testing.
Microbicides are substances intended to reduce or prevent the sexual transmission of HIV and other sexually transmitted infections when applied topically.
Tests are signaling that a microbicide gel may be able to prevent women from HIV infection, reported Dr. Salim S. Abdool Karim, professor of clinical Epidemiology at Columbia University Mailman School of Public Health, pro vice-chancellor at the University of KwaZulu-Natal in Durban, South Africa, and director the Center for the AIDS Program of Research in South Africa.
Dr. Karim led the multi-center study for the U.S.-based Microbicide Trials Network.
According to HealthNews.com, a clinical trial of 3,099 HIV-uninfected women conducted between February 2005 and September 2008 in South Africa, Zimbabwe and the United States, PRO 2000, a gel made by Massachusetts-based Indevus Pharmaceuticals, reduced the rate of HIV infection in women by 30 percent, compared to those using no gel.
Further research is needed; however, development of such a product will undoubtedly reduce the number of infected women worldwide.
“This microbicide gel would change the lives of women. Decreasing the risk of spreading HIV is the first measure scientists and doctors can take to fight this deadly disease,” said bio-med major Abby Ketner.

Currently, there are 13 microbicide candidates are in various stages of clinical development, and over 50 products are being tested pre-clinically.





